These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6190290)

  • 21. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
    Christensen MM; Bendix Holme J; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Husted SE
    Scand J Urol Nephrol; 1993; 27(1):39-44. PubMed ID: 7684157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
    Janknegt RA; Chapple CR
    Eur Urol; 1993; 24(3):319-26. PubMed ID: 7505224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
    Kadow C; Abrams PH
    Eur Urol; 1986; 12(3):187-9. PubMed ID: 2423337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
    Kirby RS
    Urology; 1995 Aug; 46(2):182-6. PubMed ID: 7542819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia].
    Vontobel HP; Herzog R; Rutishauser G; Kres H
    Urologe A; 1985 Jan; 24(1):49-51. PubMed ID: 2580383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
    Bircan K; Ozen HA; Ergen A; Başar I; Ozgür S; Ilker Y; Karaağaoğlu E; Remzi D
    Int Urol Nephrol; 1990; 22(4):345-8. PubMed ID: 1699907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study.
    Bendix Holme J; Christensen MM; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Elkjaer Husted S
    Scand J Urol Nephrol; 1994 Mar; 28(1):77-82. PubMed ID: 7516576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
    Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of candicidin on the human benign hypertrophied prostate gland.
    Keshin JG
    Int Surg; 1973 Feb; 58(2):116-22. PubMed ID: 4119813
    [No Abstract]   [Full Text] [Related]  

  • 39. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2011 May; 2011(5):CD001042. PubMed ID: 21563128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia.
    Feneley MR; Dunsmuir WD; Pearce J; Kirby RS
    Urology; 1996 May; 47(5):658-63. PubMed ID: 8650862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.